We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-17.86%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$96.5M
AUM Growth
+$26M
Cap. Flow
+$35.8M
Cap. Flow %
37.05%
Top 10 Hldgs %
76.97%
Holding
60
New
14
Increased
12
Reduced
2
Closed
28

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$12.8M
2
VTRS icon
Viatris
VTRS
+$6.56M
3
CELG
Celgene Corp
CELG
+$5.66M
4
AGN
Allergan plc
AGN
+$5.24M
5
SNY icon
Sanofi
SNY
+$4.7M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$5.49M
2
ABBV icon
AbbVie
ABBV
+$3.64M
3
BMY icon
Bristol-Myers Squibb
BMY
+$2.84M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$1.98M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$807K

Sector Composition

Rank Sector Weight
1 Healthcare 89.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$13.5M 14%
135,000
+55,000
+69% +$5.66M
SHPG
2
DELISTED
Shire pic
SHPG
$13.1M 13.57%
+76,200
New +$12.8M
PFE icon
3
Pfizer
PFE
$141B
$12.9M 13.39%
459,544
+111,724
+32% +$3.19M
AGN
4
DELISTED
Allergan plc
AGN
$7.37M 7.64%
27,500
+18,300
+199% +$5.24M
BMY icon
5
Bristol-Myers Squibb
BMY
$123B
$6.45M 6.68%
101,000
-45,000
-31% -$2.84M
VTRS icon
6
Viatris
VTRS
$19.8B
$6.3M 6.53%
+136,000
New +$6.56M
SNY icon
7
Sanofi
SNY
$105B
$4.7M 4.87%
+117,000
New +$4.7M
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.65M 3.78%
220,000
+76,000
+53% +$1.33M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$3.61M 3.74%
103,000
+13,000
+14% +$437K
LCI
10
DELISTED
Lannett Company, Inc.
LCI
$2.69M 2.79%
+37,500
New +$3.97M
CNCE
11
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2.5M 2.59%
183,000
– –
IMGN
12
DELISTED
Immunogen Inc
IMGN
$1.94M 2.01%
+228,000
New +$1.93M
ADMS
13
DELISTED
Adamas Pharmaceuticals
ADMS
$1.69M 1.75%
+117,000
New +$1.97M
NBIX icon
14
Neurocrine Biosciences
NBIX
$17.4B
$1.66M 1.72%
42,000
+15,000
+56% +$595K
QURE icon
15
uniQure
QURE
$2.73B
$1.37M 1.42%
115,000
+79,000
+219% +$1.17M
EGRX
16
PUT
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.34M 1.38%
+33,000
New +$2.09M
IMDZ
17
DELISTED
Immune Design Corp.
IMDZ
$1.11M 1.15%
85,138
+45,138
+113% +$521K
RXDX
18
DELISTED
Ignyta, Inc.
RXDX
$1.02M 1.05%
+150,000
New +$1.23M
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$988K 1.02%
70,000
+22,000
+46% +$297K
ADXS
20
DELISTED
Advaxis Inc
ADXS
$903K 0.94%
6,667
+2,983
+81% +$330K
FPRX
21
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$813K 0.84%
20,000
-1,500
-7% -$51.6K
IOVA icon
22
Iovance Biotherapeutics
IOVA
$2.24B
$774K 0.8%
152,266
– –
INFI
23
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$764K 0.79%
+145,000
New +$887K
AERI
24
DELISTED
Aerie Pharmaceuticals
AERI
$733K 0.76%
60,280
+32,040
+113% +$507K
INSM icon
25
Insmed
INSM
$23.2B
$507K 0.53%
+40,000
New +$526K
1
2 3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Nexthera Capital held 60 positions worth $96.5M, up 37% from $70.5M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Nexthera Capital deployed $35.8M of net new capital in Q1 2016, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Shire pic: 76,200 shares worth $13.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $2.84M trimmed.

  • Nexthera Capital's largest Q1 2016 buy was Shire pic: 76,200 shares worth $13.1M.
  • Nexthera Capital added most to Celgene Corp in Q1 2016, an estimated $5.66M increase.
  • Nexthera Capital's biggest Q1 2016 reduction was Bristol-Myers Squibb, cutting an estimated $2.84M.
  • Nexthera Capital fully exited Merck in Q1 2016, selling an estimated $5.49M.
  • Nexthera Capital's ten largest holdings make up 77% of its $96.5M portfolio in Q1 2016.
  • Nexthera Capital opened 14 new positions and closed 28 in Q1 2016.
  • Nexthera Capital's portfolio value rose 37% quarter-over-quarter to $96.5M.

Based on Nexthera Capital's 13F filing for Q1 2016, filed 13 May 2016.